Publikationen
Hier finden Sie eine chronologische Liste der Veröffentlichungen der Nachwuchsgruppe.
Zeige Ergebnisse 1 bis 10 von 11.
Publikation
| 2023
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing.
- Lyons DE, Kumar P, Roan NR, Defechereux PA, Feschotte C, Lange UC, Murthy N, Sameshima P, Verdin E, Ake JA, Parsons MS, Nath A, Gianella S, Smith DM, Kallas EG, Villa TJ, Strange R, Mwesigwa B, Furler O'Brien RL, Nixon DF, Ndhlovu LC, Valente ST, Ott M
-
Viruses,
Publikation
| 2023
Publikation
| 2021
Improved targeting of human CD4+ T cells by nanobody-modified AAV2 gene therapy vectors.
- Hamann MV, Beschorner N, Vu XK, Hauber I, Lange UC, Traenkle B, Kaiser PD, Foth D, Schneider C, Büning H, Rothbauer U, Hauber J
-
PLoS One,
Publikation
| 2020
Transcriptional behavior of the HIV-1 promoter in context of the BACH2 prominent proviral integration gene.
- Hamann MV, Ehmele P, Verdikt R, Bialek-Waldmann JK, Virdi S, Günther T, Van Lint C, Grundhoff A, Hauber J, Lange UC
-
Virus Res,
Publikation
| 2020
Epigenetic crosstalk in chronic infection with HIV-1.
- Lange UC, Verdikt R, Ait-Ammar A, Van Lint C
-
Semin Immunopathol,
Publikation
| 2019
A comparative epigenome analysis of gammaherpesviruses suggests cis-acting sequence features as critical mediators of rapid polycomb recruitment.
- Günther T, Fröhlich J, Herrde C, Ohno S, Burkhardt L, Adler H, Grundhoff A
-
PLoS Pathog,
Publikation
| 2018
CRISPR-Cas9-based Genome Engineering to Generate Jurkat Reporter Models for HIV-1 Infection with Selected Proviral Integration Sites.
- Bialek JK, Walther T, Hauber J, Lange UC
-
J Vis Exp,
Publikation
| 2018
STK3 is a therapeutic target for a subset of acute myeloid leukemias.
- Camgoz A, Paszkowski-Rogacz M, Satpathy S, Wermke M, Hamann MV, von Bonin M, Choudhary C, Knapp S, Buchholz F
-
Oncotarget,
Publikation
| 2018
Pinpointing recurrent proviral integration sites in new models for latent HIV-1 infection.
- Lange UC, Bialek JK, Walther T, Hauber J
-
Virus Res,
Publikation
| 2016
Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
- Bialek JK, Dunay GA, Voges M, Schäfer C, Spohn M, Stucka R, Hauber J, Lange UC
-
PLoS One,
